VANCOUVER, Jan. 21, 2019 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that the Company's wholly-owned subsidiary 0989561 B.C. Ltd. ("Canandia") has received a sales license for its Delta location (the "Delta Facility") from Health Canada effective January 18, 2019, pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Delta Facility includes a cultivation, production and research facility, designed to highlight our capabilities as producers and breeders of superior cannabis strains.
Canandia's second asset is located in Mission (the "Mission Location"), British Columbia. The Mission Location includes 32 acres of buildable land, expandable up to 1 million square feet of production capacity under one Cannabis Act and Cannabis Regulations license. The Mission Location taps into wholesale energy costs with 38 MG Watt service at the property line, and boasts access to underground aquifers, making it a strategically attractive and cost competitive addition to Invictus' current cultivation footprint once developed and commissioned.
"We are thrilled to have achieved another major milestone with our second sales license awarded by Health Canada," said George E. Kveton, President and CEO of Invictus. "We have hit the ground running in 2019, remaining laser focused on our objective to bring new facilities online to cultivate unique strain varieties required for our medical and adult use recreational product portfolio."
"I am exceptionally proud of our in-house Pharmaceutical Regulatory Compliance Team today," said Alon Amit CEO of Canandia. "Dr. Jaclyn Thompson, Quality Assurance Supervisor, and Director of Research, and her team are behind the issuance of our sales license months ahead of schedule, and the smooth successful migration of our license issued under the ACMPR to the Cannabis Act and its regulations. We look forward to supplying the Canadian medical and recreational markets with our menu of exotic cannabis strains"
Canandia represents the Company's third cultivation license and second sales license issued by Health Canada under the Cannabis Act and Cannabis Regulations. Invictus' production footprint includes licensed cannabis operations in British Columbia, Alberta and Ontario.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director
Vice President, Public Relations and Regulatory Affairs
Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.
Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with three cannabis production facilities licensed under the Cannabis Act and Cannabis Regulations in Canada. To accommodate international sales, Invictus' wholly-owned subsidiary, Acreage Pharms Ltd. ("Acreage Pharms"), has designed and is currently building its Phase 3 purpose-built cultivation facility to be European Union Good Manufacturing Practices ("EU-GMP") compliant. The Company is targeting up to 50 percent of production to medical cannabis. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd. ("Future Harvest"), a high-quality fertilizer and nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 70 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. For more information visit www.invictus-md.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE Invictus MD Strategies